Chemotherapy regimens in early breast cancer: major controversies and future outlook

References

• Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814), 432–444 (2012).
   PubMed Web of Science ®Google Scholar
• De Laurentiis M, Cancello G, D’Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26(1), 44–53 (2008).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22(8), 1736–1747 (2011).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Practice Guidelines in Oncology – v.1.2012. (2012).
   Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21(17), 3357–3365 (2003).
   PubMed Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21(8), 1431–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J et al.; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352(22), 2302–2313 (2005).
   PubMed Web of Science ®Google Scholar
• Roché H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J. Clin. Oncol. 24(36), 5664–5671 (2006).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Ravdin PM et al.; Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a Phase 3, open-label, randomised controlled trial. Lancet 374(9707), 2055–2063 (2009).
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol. 8(9), 1483–1496 (1990).
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Green SJ, Ravdin PM et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J. Clin. Oncol. 23(33), 8313–8321 (2005).
   PubMed Web of Science ®Google Scholar
• Levine MN, Bramwell V, Pritchard K et al. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. Eur. J. Cancer 29A(1), 37–43 (1992).
   PubMed Web of Science ®Google Scholar
• Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 16(8), 2651–2658 (1998).
   PubMed Web of Science ®Google Scholar
• Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N; National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J. Clin. Oncol. 23(22), 5166–5170 (2005).
   PubMed Web of Science ®Google Scholar
• Martin M, Villar A, Sole-Calvo A et al.; GEICAM Group (Spanish Breast Cancer Research Group), Spain. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann. Oncol. 14(6), 833–842 (2003).
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Roché H, Kerbrat P et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J. Clin. Oncol. 23(12), 2686–2693 (2005).
   PubMed Web of Science ®Google Scholar
• Trudeau M, Charbonneau F, Gelmon K et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 6(11), 886–898 (2005).
   PubMed Web of Science ®Google Scholar
• Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl Cancer Inst. 90(16), 1205–1211 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. Oncol. 15(5), 1858–1869 (1997).
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21(6), 976–983 (2003).
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Di Leo A, Beauduin M et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J. Clin. Oncol. 19(12), 3103–3110 (2001).
   PubMed Web of Science ®Google Scholar
• Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330(18), 1260–1266 (1994).
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Bruzzi P, Nicolò G et al. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br. J. Cancer 93(1), 7–14 (2005).
   PubMed Web of Science ®Google Scholar
• Hayes DF, Thor AD, Dressler LG et al.; Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357(15), 1496–1506 (2007).
   PubMed Web of Science ®Google Scholar
• Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl Cancer Inst. 100(1), 14–20 (2008).
   PubMed Web of Science ®Google Scholar
• Dhesy-Thind B, Pritchard KI, Messersmith H, O’Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res. Treat. 109(2), 209–229 (2008).
   PubMed Web of Science ®Google Scholar
• Järvinen TA, Liu ET. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIα (TOP2A) genes – molecular basis for combination chemotherapy in cancer. Curr. Cancer Drug Targets 6(7), 579–602 (2006).
   PubMed Web of Science ®Google Scholar
• O’Malley FP, Chia S, Tu D et al. Topoisomerase II α protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res. Treat. 128(2), 401–409 (2011).
   PubMed Web of Science ®Google Scholar
• Press MF, Sauter G, Buyse M et al. Alteration of topoisomerase II-α gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J. Clin. Oncol. 29(7), 859–867 (2011).
   PubMed Web of Science ®Google Scholar
• Olsen KE, Knudsen H, Rasmussen BB et al.; Danish Breast Cancer Co-operative Group. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 43(1), 35–42 (2004).
   PubMed Web of Science ®Google Scholar
• Järvinen TA, Tanner M, Bärlund M, Borg A, Isola J. Characterization of topoisomerase II α gene amplification and deletion in breast cancer. Genes. Chromosomes Cancer 26(2), 142–150 (1999).
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 8(5), 1107–1116 (2002).
   PubMed Web of Science ®Google Scholar
• Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN. Role of anthracyclines in the treatment of early breast cancer. J. Clin. Oncol. 27(28), 4798–4808 (2009).
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J. Clin. Oncol. 19(4), 931–942 (2001).
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. 23(16), 3686–3696 (2005).
   PubMed Web of Science ®Google Scholar
• Kataja V, Castiglione M; ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 10–14 (2009).
   PubMed Web of Science ®Google Scholar
• Foon KA, Lutzky J, Baral RN et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. 18(2), 376–384 (2000).
   PubMed Web of Science ®Google Scholar
• Martín M, Rodríguez-Lescure A, Ruiz A et al.; GEICAM 9906 Study Investigators. Randomized Phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J. Natl Cancer Inst. 100(11), 805–814 (2008).
   PubMedGoogle Scholar
• Burnell M, Levine MN, Chapman JA et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J. Clin. Oncol. 28(1), 77–82 (2010).
   PubMed Web of Science ®Google Scholar
• Polyzos A, Malamos N, Boukovinas I et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res. Treat. 119(1), 95–104 (2010).
   PubMed Web of Science ®Google Scholar
• Francis P, Crown J, Di Leo A et al.; BIG 02-98 Collaborative Group. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J. Natl Cancer Inst. 100(2), 121–133 (2008).
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, O’Neill A, Sparano JA et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J. Clin. Oncol. 26(25), 4092–4099 (2008).
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O’Shaughnessy J et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J. Clin. Oncol. 27(8), 1177–1183 (2009).
   PubMed Web of Science ®Google Scholar
• Qin YY, Li H, Guo XJ et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS ONE 6(11), e26946 (2011).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358(16), 1663–1671 (2008).
   PubMed Web of Science ®Google Scholar
• Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with ‘curability’ of experimental leukemia. Cancer Chemother. Rep. 35, 1–111 (1964).
   PubMedGoogle Scholar
• Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med. 333(22), 1456–1461 (1995).
   PubMed Web of Science ®Google Scholar
• Norton L, Simon R. The Norton–Simon hypothesis revisited. Cancer Treat. Rep. 70(1), 163–169 (1986).
   PubMedGoogle Scholar
• Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 48(24 Pt 1), 7067–7071 (1988).
   PubMed Web of Science ®Google Scholar
• Venturini M, Del Mastro L, Aitini E et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J. Natl Cancer Inst. 97(23), 1724–1733 (2005).
   PubMed Web of Science ®Google Scholar
• Moebus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO Phase III study. J. Clin. Oncol. 28(17), 2874–2880 (2010).
   PubMed Web of Science ®Google Scholar
• Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al.; EORTC. Final results of a randomized Phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J. Clin. Oncol. 21(5), 843–850 (2003).
   PubMed Web of Science ®Google Scholar
• Kümmel S, Krocker J, Kohls A et al. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br. J. Cancer 94(9), 1237–1244 (2006).
   PubMed Web of Science ®Google Scholar
• Lemos Duarte I, da Silveira Nogueira Lima JP, Passos Lima CS, Deeke Sasse A. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis. Breast 21(3), 343–349 (2012).
   PubMed Web of Science ®Google Scholar
• Baldini E, Gardin G, Giannessi PG et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized Phase III trial in locally advanced breast cancer. Ann. Oncol. 14(2), 227–232 (2003).
   PubMed Web of Science ®Google Scholar
• Jones RL, Walsh G, Ashley S et al. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br. J. Cancer 100(2), 305–310 (2009).
   PubMed Web of Science ®Google Scholar
• Loi S, Piccart M, Sotiriou C. The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit. Rev. Oncol. Hematol. 61(3), 187–194 (2007).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv. Anat. Pathol. 19(1), 39–53 (2012).
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101(10), 736–750 (2009).
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361(8), 766–776 (2009).
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M et al.; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453), 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Pagani O, Gelber S, Simoncini E et al.; International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res. Treat. 116(3), 491–500 (2009).
   PubMed Web of Science ®Google Scholar
• Regan MM, Pagani O, Walley B et al.; SOFT/TEXT/PERCHE Steering Committee; International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann. Oncol. 19(7), 1231–1241 (2008).
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Price KN, Gelber RD et al. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res. Treat. 113(1), 137–144 (2009).
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol. 4(4), 459–471 (1986).
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Legault-Poisson S et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J. Clin. Oncol. 8(6), 1005–1018 (1990).
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl Cancer Inst. 89(22), 1673–1682 (1997).
   PubMed Web of Science ®Google Scholar
• International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J. Natl Cancer Inst. 94(14), 1054–1065 (2002).
   PubMedGoogle Scholar
• Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14), 1658–1667 (2006).
   PubMed Web of Science ®Google Scholar
• Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 24(7), 1037–1044 (2006).
   PubMed Web of Science ®Google Scholar
• Mazouni C, Kau SW, Frye D et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann. Oncol. 18(5), 874–880 (2007).
   PubMed Web of Science ®Google Scholar
• Colleoni M, Bagnardi V, Rotmensz N et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res. Treat. 116(2), 359–369 (2009).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790–800 (2009).
   PubMed Web of Science ®Google Scholar
• Filipits M, Rudas M, Jakesz R et al.; EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17(18), 6012–6020 (2011).
   PubMed Web of Science ®Google Scholar
• Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12(6), 631–635 (2007).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006).
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726–3734 (2006).
   PubMed Web of Science ®Google Scholar
• Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10(4), R65 (2008).
   PubMed Web of Science ®Google Scholar
• Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24(19), 2200–2208 (2008).
   PubMed Web of Science ®Google Scholar
• van ‘t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• van de Vijver M. Gene-expression profiling and the future of adjuvant therapy. Oncologist, 10(Suppl. 2), 30–34 (2005).
   PubMed Web of Science ®Google Scholar
• Buyse M, Loi S, van’t Veer L et al.; TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98(17), 1183–1192 (2006).
   PubMed Web of Science ®Google Scholar
• Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26(5), 729–735 (2008).
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37(7), 541–548 (2004).
   PubMed Web of Science ®Google Scholar
• Harbeck N, Kates RE, Schmitt M et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin. Breast Cancer 5(5), 348–352 (2004).
   PubMedGoogle Scholar
• Sweep CG, Geurts-Moespot J, Grebenschikov N et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br. J. Cancer 78(11), 1434–1441 (1998).
   PubMed Web of Science ®Google Scholar
• Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl Cancer Inst. 94(2), 116–128 (2002).
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R et al.; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25(33), 5287–5312 (2007).
   PubMed Web of Science ®Google Scholar
• Kreienberg R, Kopp I, Albert U, Bartsch HH. Interdisziplinäre S3-Leitlinie für die Diagnostik. Therapie und Nachsorge des Mammakarzinoms (2008).
   Google Scholar
• Metzger-Filho O, Tutt A, de Azambuja E et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30(15), 1879–1887 (2012).
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Paterson AH, Fine S et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J. Clin. Oncol. 15(6), 2302–2311 (1997).
   PubMed Web of Science ®Google Scholar